The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis

There is an urgent requirement for safe, oral and cost-effective drugs for the treatment of visceral leishmaniasis (VL). We report that delamanid (OPC-67683), an approved drug for multi-drug resistant tuberculosis, is a potent inhibitor of Leishmania donovani both in vitro and in vivo. Twice-daily o...

Descripción completa

Detalles Bibliográficos
Autores principales: Patterson, Stephen, Wyllie, Susan, Norval, Suzanne, Stojanovski, Laste, Simeons, Frederick RC, Auer, Jennifer L, Osuna-Cabello, Maria, Read, Kevin D, Fairlamb, Alan H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2016
Materias:
Microbiology and Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878867/
https://www.ncbi.nlm.nih.gov/pubmed/27215734
http://dx.doi.org/10.7554/eLife.09744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878867/
https://www.ncbi.nlm.nih.gov/pubmed/27215734
http://dx.doi.org/10.7554/eLife.09744

Ejemplares similares